A 52-year-old woman with type 2 diabetes, CKD stage 3b (eGFR 38), and heart failure with reduced ejection fraction (HFrEF, EF 35%) presents for medication review. Which antidiabetic agent provides both cardiovascular mortality benefit and renal protection most appropriate for her combined conditions?

Remaining questions and full explanations are VIP-exclusive.